Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients who have advanced myelodysplastic syndrome , acute myelogenous leukemia or chronic lymphocytic leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Salicylates; Salicylic Acid; Salicylsalicylic acid; Sodium Salicylate

Criteria

DISEASE CHARACTERISTICS:

• Relapsed or refractory acute myelogenous leukemia OR

• Elderly patients with newly diagnosed acute myelogenous leukemia not eligible for standard therapy OR

• "High-risk" myelodysplastic syndrome, including:

• Refractory anemia with excess blasts

• Refractory anemia with excess blasts in transformation

• Chronic myelomonocytic leukemia OR

• Relapsed or refractory chronic lymphocytic leukemia

• Not eligible for transplant protocols at MSKCC or refuses transplant

• Not eligible for a higher priority protocol (e.g., bone marrow transplantation)

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Platelet count at least 25,000/mm^3

Hepatic:

• Bilirubin no greater than 2.0 mg/dL

• Transaminase levels less than 3 times upper limit of normal

• PT no greater than 14 seconds

• PTT no greater than 34.6 seconds

Renal:

• Creatinine no greater than 2.0 mg/dL OR

• Creatinine clearance greater than 60 mL/min

Other:

• Not pregnant or nursing

• No history of abnormal bleeding or unexplained bleeding disorders

• No history of peptic ulcer disease

• No salicylate allergy

• No other concurrent active malignancy

• No other concurrent illness that would preclude study assessment to a significant degree

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• Not specified

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified